EUVIMEDOpdag EUVIMED
Vergleichsstudie

Progression to Psoriatic Arthritis Among Psoriasis Patients Treated With JAK Inhibitors Compared With IL-17/23 Inhibitors

Robert Adler, Michael Kozlov, Sara Sash, Manan D Mehta, Emily Cowen, Katerina Svigos, Jessica Lori Feig

Journal of Drugs in Dermatology · 2026-11-01 · 25 (11) · 997-1002

DOI: 10.36849/jdd.9963 ↗

At a glance

Vergleichsstudie in Journal of Drugs in Dermatology, published online on 2026-10-01. Written by Robert Adler and 6 co-authors. Major MEDLINE topics: Arthritis, Psoriatic, Interleukin-17, Interleukin-23, Janus Kinase Inhibitors.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory disease that may progress to psoriatic arthritis (PsA). Although multiple systemic therapies are available, including interleukin (IL)-17 and IL-23 inhibitors and Janus kinase (JAK) inhibitors, their comparative associations with incident PsA remain incompletely characterized. METHODS: We performed 2 retrospective, propensity score-matched cohort studies within a large federated research network using a TARGET trial emulation framework. Adults with psoriasis initiating a JAK inhibitor were separately compared with those initiating an IL-17 inhibitor or an IL-23 inhibitor; patients with preexisting PsA were excluded. Cohorts were matched 1:1 on demographics, race and ethnicity, comorbidities, psoriasis subtype, baseline musculoskeletal symptoms, prior medication exposure, and healthcare utilization. Balance was assessed using standardized mean differences (

Subjects

MeSH terms (MEDLINE)

Arthritis, PsoriaticInterleukin-17Interleukin-23Janus Kinase InhibitorsPsoriasisHumansFemaleRetrospective StudiesMaleMiddle AgedAdultDisease ProgressionIncidencePropensity ScoreCohort Studies

Substances

Interleukin-17Interleukin-23Janus Kinase Inhibitors

Cite

APA

Adler, R., Kozlov, M., Sash, S., Mehta, M. D., Cowen, E., Svigos, K., & Feig, J. L. (2026). Progression to Psoriatic Arthritis Among Psoriasis Patients Treated With JAK Inhibitors Compared With IL-17/23 Inhibitors. Journal of Drugs in Dermatology, 25(11), 997-1002. https://doi.org/10.36849/jdd.9963

Vancouver

Adler R, Kozlov M, Sash S, Mehta MD, Cowen E, Svigos K, et al. Progression to Psoriatic Arthritis Among Psoriasis Patients Treated With JAK Inhibitors Compared With IL-17/23 Inhibitors. Journal of Drugs in Dermatology. 2026;25(11):997-1002. doi:10.36849/jdd.9963

BibTeX
@article{Adler2026,
  author = {Adler, Robert and Kozlov, Michael and Sash, Sara and Mehta, Manan D and Cowen, Emily and Svigos, Katerina and Feig, Jessica Lori},
  title = {Progression to Psoriatic Arthritis Among Psoriasis Patients Treated With JAK Inhibitors Compared With IL-17/23 Inhibitors},
  journal = {Journal of Drugs in Dermatology},
  year = {2026},
  volume = {25},
  number = {11},
  pages = {997--1002},
  doi = {10.36849/jdd.9963}
}
Start for free →